Aaron Siri - a lawyer with a history of seeking to expand exemptions to vaccines- asked the FDA to suspend or withdraw ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

The company announced it achieved the first milestone under its Sanofi partnership, earning a $50 million payment for ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...

In 2018 an investigation by the International Consortium of Investigative Journalists revealed that 83,000 deaths and over ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Argus has recently reiterated Sanofi SA (SNY) stock to Buy rating, as announced on July 26, 2024, according to Finviz. Earlier, on January 23, 2024, Morgan Stanley had initiated the stock research ...